PCOS Becomes PMOS: A New Understanding of Women's Hormonal and Metabolic Health
For many years, Polycystic Ovary Syndrome (PCOS) has been one of the most commonly diagnosed hormonal disorders affecting women. Despite its name, however, the condition has long been recognised as being far more complex than simply a problem involving the ovaries.
Following more than 14 years of international research and collaboration, experts have proposed a new name: Polyendocrine Metabolic Ovarian Syndrome (PMOS). For many women, this represents more than a change in terminology. It reflects a broader understanding of the condition as a whole-body disorder involving hormonal, metabolic, and reproductive health.
Why Was PCOS Renamed?
The term "Polycystic Ovary Syndrome" has been criticised for decades because it is both misleading and scientifically inaccurate. Many women diagnosed with PCOS do not actually have ovarian cysts. Instead, ultrasound imaging may reveal multiple immature follicles, while some women with the condition have no ovarian changes visible at all.
The original name also placed too much emphasis on fertility and reproductive symptoms, despite the condition affecting multiple systems throughout the body. Researchers and patient groups have argued that this narrow focus has contributed to confusion, delayed diagnosis, and inadequate recognition of the broader health implications.
What Is PMOS?
PMOS is a complex endocrine and metabolic condition that affects women across the lifespan. It is characterised by hormonal imbalances, altered ovarian function, and disturbances in metabolism, particularly insulin regulation.
Symptoms vary considerably between individuals but may include:
Irregular or absent menstrual cycles
Difficulty conceiving or irregular ovulation
Acne and oily skin
Excess facial or body hair
Hair thinning or scalp hair loss
Weight gain or difficulty losing weight
Fatigue and low energy
Insulin resistance and blood sugar dysregulation
Women with PMOS may also have an increased risk of developing type 2 diabetes, cardiovascular disease, fatty liver disease, and other metabolic complications.
How Is PMOS Diagnosed?
There is currently no single test that confirms PMOS. Diagnosis is based on a combination of symptoms, blood tests, and ultrasound findings, while also excluding other possible causes.
Current international guidelines generally use the Rotterdam criteria, requiring two of the following three features:
Irregular or absent ovulation.
Clinical or biochemical evidence of elevated androgens, which may present as acne, excess hair growth, or hair loss.
Polycystic ovarian appearance on ultrasound.
Blood tests commonly used during assessment may include:
Testosterone and other androgen levels
Sex hormone-binding globulin (SHBG)
Luteinising hormone (LH) and follicle-stimulating hormone (FSH)
Thyroid function tests
Prolactin
Fasting glucose and insulin
HbA1c
Lipid profile
These investigations help provide a clearer picture of hormonal and metabolic health and guide treatment decisions.
What Does PMOS Mean?
The new name, Polyendocrine Metabolic Ovarian Syndrome (PMOS), provides a more accurate description of the condition. Polyendocrine recognises that multiple hormone systems are involved, not just the ovaries. Metabolic highlights the strong links with insulin resistance, blood sugar regulation, weight management, and long-term metabolic health. Ovarian acknowledges the important role the ovaries play in ovulation and reproductive function, while Syndrome reflects the fact that symptoms can vary considerably from woman to woman, with no two individuals experiencing the condition in exactly the same way.
Why Does the Name Change Matter?
The transition from PCOS to PMOS represents a significant shift in the understanding of women's health. It acknowledges that the condition affects much more than fertility and recognises the important role of metabolism, insulin sensitivity, cardiovascular health, and overall wellbeing.
Experts hope that the new terminology will encourage:
Earlier diagnosis.
Better metabolic screening.
More comprehensive and individualised treatment.
Increased research funding.
Greater awareness among healthcare professionals and the public.
Reduced stigma and misunderstanding.
Importantly, the condition itself has not changed, and current diagnostic criteria and treatment approaches remain largely the same. However, the new terminology is expected to gradually influence future clinical guidelines, medical education, and research priorities.
Looking Beyond Fertility
For many women, the move from PCOS to PMOS is validating. It acknowledges what patients and healthcare practitioners have recognised for many years—that this is not simply an ovarian disorder, but a complex endocrine and metabolic condition that affects the whole body and often changes throughout life.
By shifting the focus beyond fertility alone, the new name encourages a more holistic approach to women's health and highlights the importance of supporting long-term metabolic, hormonal, and overall wellbeing.
References
Teede HJ, et al. International recommendations and consensus discussions regarding the renaming of Polycystic Ovary Syndrome. The Lancet. 2026.
European Congress of Endocrinology. Proceedings and consensus presentations, Prague, Czech Republic, 2026.
Monash University Centre for Research Excellence in Women's Health and Reproductive Life. International PCOS Guideline Collaboration.
Teede HJ, Misso ML, Costello MF, et al. Recommendations from the International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction. 2018;33(9):1602-1618.
International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Monash University and collaborating societies. Updated recommendations.
Disclaimer
This article is intended for educational purposes only and should not be considered medical advice. Information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare practitioner or medical specialist regarding any health concerns or before making changes to your treatment plan.
